CANGRELOR
Cangrelor is a medication used during percutaneous coronary intervention (PCI) to help prevent complications during the procedure. It helps patients by lowering the risk of heart attacks, the formation of blood clots in stents, and the need for repeat coronary procedures. This drug is specifically used for individuals who have not yet been treated with other P2Y12 platelet inhibitors or certain other blood-thinning medications like glycoprotein IIb/IIIa inhibitors.
How CANGRELOR Works
This drug works by selectively and reversibly binding to the P2Y12 receptor on platelets. By blocking this receptor, it prevents ADP from activating the platelets and causing them to clump together. This action stops the signaling process that leads to platelet aggregation during medical procedures.
Details
- Status
- Prescription
- First Approved
- 2025-08-11
- Routes
- INTRAVENOUS
- Dosage Forms
- POWDER
CANGRELOR Approval History
What CANGRELOR Treats
2 indicationsCANGRELOR is approved for 2 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Myocardial Infarction
- Stent Thrombosis
CANGRELOR Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to CANGRELOR
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
16 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07225842 BIRDGE 2 | IRB202500991 | Ph 4 | recruiting | The Bridging Antiplatelet Therapy With Cangrelor 2 Study |
| NCT04667078 REPERFUSE | MMI_2020_35 | Ph 3 | recruiting | REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts |
| NCT02733341 results posted | 2015CAR77 | Ph 4 | completed | The Effect of IV Cangrelor and Oral Ticagrelor Study |
| NCT03551964 DAPT-SHOCK-AMI | 13062017-23-1 2018-002161-19 | Ph 4 | completed | Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction |
| NCT06792643 SURVIVE | SURVIVE | Ph 2 | recruiting | Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO |
| NCT04668144 SWAP-6 results posted | SMF-02 | Ph 4 | completed | Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI |
| NCT04634162 SWAP-5 results posted | SMF-01 | Ph 4 | completed | PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment |
| NCT02765633 | MDCO-CAN-15-01 2016-000134-22 | Ph 1 | completed | Cangrelor Neonatal PK/PD and Safety Study |
| NCT03247738 CANTIC results posted | IIS CHI001 WIRB | Ph 4 | completed | Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI |
| NCT03043274 results posted | 16-0990-F6A | Ph 4 | terminated | Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size |
| NCT01979445 BRIDGE results posted | MDCO-CAN-13-02 | Ph 2 | completed | Cangrelor to Clopidogrel or Prasugrel Transition Study |
| NCT02978040 FABOLUS-FASTER | FABOLUS-FASTER | Ph 4 | completed | Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI. |
| NCT01852019 results posted | MDCO-CAN-13-01 | Ph 2 | completed | Cangrelor Prasugrel Transition Study |
| NCT01766466 results posted | MDCO-CAN-12-03 | Ph 2 | completed | Cangrelor Ticagrelor Transition Study |
| NCT00767507 Bridge results posted | TMC-CAN-08-02 | Ph 2 | completed | Maintenance of Platelet Inhibition With Cangrelor |
| NCT00699504 | TMC CAN 08 01 | Ph 1 | completed | Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CANGRELOR FDA Label Details
Indications & Usage
CANGRELOR is indicated for the treatment of Myocardial Infarction; Stent Thrombosis.
Looking for the branded version?
KENGREAL
Full clinical data, patents, trials, and competitive landscape for cangrelor.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.